全文获取类型
收费全文 | 9960篇 |
免费 | 1240篇 |
国内免费 | 68篇 |
专业分类
耳鼻咽喉 | 106篇 |
儿科学 | 381篇 |
妇产科学 | 156篇 |
基础医学 | 1356篇 |
口腔科学 | 463篇 |
临床医学 | 1391篇 |
内科学 | 2631篇 |
皮肤病学 | 255篇 |
神经病学 | 819篇 |
特种医学 | 112篇 |
外科学 | 972篇 |
综合类 | 35篇 |
一般理论 | 4篇 |
预防医学 | 1048篇 |
眼科学 | 161篇 |
药学 | 619篇 |
中国医学 | 50篇 |
肿瘤学 | 709篇 |
出版年
2024年 | 26篇 |
2023年 | 211篇 |
2022年 | 246篇 |
2021年 | 403篇 |
2020年 | 386篇 |
2019年 | 293篇 |
2018年 | 503篇 |
2017年 | 380篇 |
2016年 | 427篇 |
2015年 | 425篇 |
2014年 | 585篇 |
2013年 | 690篇 |
2012年 | 767篇 |
2011年 | 782篇 |
2010年 | 532篇 |
2009年 | 534篇 |
2008年 | 652篇 |
2007年 | 562篇 |
2006年 | 534篇 |
2005年 | 460篇 |
2004年 | 424篇 |
2003年 | 402篇 |
2002年 | 345篇 |
2001年 | 56篇 |
2000年 | 60篇 |
1999年 | 76篇 |
1998年 | 84篇 |
1997年 | 56篇 |
1996年 | 55篇 |
1995年 | 54篇 |
1994年 | 40篇 |
1993年 | 32篇 |
1992年 | 17篇 |
1991年 | 16篇 |
1990年 | 16篇 |
1989年 | 16篇 |
1988年 | 17篇 |
1987年 | 16篇 |
1986年 | 11篇 |
1985年 | 11篇 |
1984年 | 12篇 |
1983年 | 9篇 |
1982年 | 11篇 |
1981年 | 6篇 |
1980年 | 5篇 |
1979年 | 3篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1973年 | 2篇 |
1970年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 172 毫秒
101.
Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. 总被引:7,自引:0,他引:7
Fabio Pastorino Chiara Brignole Danilo Marimpietri Gabriella Pagnan Adriana Morando Domenico Ribatti Sean C Semple Claudio Gambini Theresa M Allen Mirco Ponzoni 《Clinical cancer research》2003,9(12):4595-4605
PURPOSE: Melanoma is a highly malignant and increasingly common tumor. Because the cure rate of metastatic melanoma by conventional treatment is very low, new therapeutic approaches are needed. We previously reported that coated cationic liposomes (CCL) targeted with a monoclonal antibody against the disialoganglioside (GD(2)) and containing c-myb antisense oligodeoxynucleotides (asODNs) resulted in a selective inhibition of the proliferation of GD(2)-positive neuroblastoma cells in vitro. EXPERIMENTAL DESIGN: Here, we tested the in vivo antitumor effects of this novel antisense liposomal formulation by targeting the c-myc oncogene on melanoma, a neuroectodermal tumor sharing with neuroblastoma the expression of GD(2). RESULTS: Our methods produced GD(2)-targeted liposomes that stably entrapped 90% of added c-myc asODNs. These liposomes showed a selective binding for GD(2)-positive melanoma cells in vitro. Melanoma cell proliferation was inhibited to a greater extent by GD(2)-targeted liposomes containing c-myc asODNs (aGD(2)-CCL-myc-as) than by nontargeted liposomes or free asODNs. The pharmacokinetic results obtained after i.v. injection of [(3)H]-myc-asODNs, free or encapsulated in nontargeted CCLs or GD(2)-targeted CCLs, showed that free c-myc-asODNs were rapidly cleared, with less than 10% of the injected dose remaining in blood at 30 min after injection. c-myc-asODNs encapsulated within either CCL or aGD(2)-CCL demonstrated a more favorable profile in blood, with about 20% of the injected dose of each preparation remaining in vivo at 24 h after injection. In an in vivo melanoma experimental metastatic model, aGD(2)-CCL-myc-as, at a total dose of only 10 mg of asODN per kilogram, significantly inhibited the development of microscopic metastases in the lung compared with animals treated with myc-asODNs, free or entrapped in nontargeted liposomes, or aGD(2)-CCL encapsulating scrambled asODNs (P < 0.01). Moreover, mice bearing established s.c. human melanoma xenografts treated with aGD(2)-CCL-myc-as exhibited significantly reduced tumor growth and increased survival (P < 0.01 versus control mice). The mechanism for the antitumor effects appears to be down-regulation of the expression of the c-myc protein and interruption of c-myc-mediated signaling: induction of p53 and inhibition of Bcl-2 proteins, leading to extensive tumor cell apoptosis. CONCLUSION: These results suggest that inhibition of c-myc proto-oncogene by GD(2)-targeted antisense therapy could provide an effective approach for the treatment of melanoma in an adjuvant setting. 相似文献
102.
Economic Burden of Patients with Anemia in Selected Diseases 总被引:1,自引:0,他引:1
William B. Ershler MD Kristina Chen PharmD MS Eileen B. Reyes Robert Dubois MD PhD 《Value in health》2005,8(6):629-638
103.
104.
Montserrat Vera-Llonch MD MPH Thomas E. Delea MSIA Erin Richardson BS Marcia Rupnow PhD Amy Grogg PharmD Gerry Oster PhD 《Value in health》2004,7(5):569-584
OBJECTIVE: To compare expected outcomes and costs of care in patients with chronic schizophrenia or schizoaffective disorders who are treated with risperidone versus olanzapine. METHODS: A Markov model was developed to examine outcomes and costs of care in patients with chronic schizophrenia or schizoaffective disorders receiving risperidone or olanzapine. The time frame of interest was 1 year. The model focused particular attention on the likelihood of therapy switching and discontinuation as a result of treatment-emergent side effects, as the efficacy of these two agents is similar. Measures of interest included the incidence of relapse and selected side effects including extrapyramidal symptoms (EPS), prolactin-related disorders and diabetes, expected change in body weight, and the percentage of patients remaining on initial therapy at the end of 1 year. Costs of antipsychotic therapy and psychiatric and nonpsychiatric services also were examined. RESULTS: At 1 year, the rate of EPS was estimated to be slightly higher for risperidone, as was the incidence of symptomatic prolactin-related disorders. The expected incidence of diabetes mellitus, while low, was slightly higher for olanzapine. Approximately 25% and 4% of olanzapine and risperidone patients, respectively, were projected to experience an increase in body weight > or = 7%. The estimated percentage of patients remaining on initial therapy at the end of 1 year was higher for risperidone than olanzapine (76.9% vs. 45.6%, respectively). Expected mean total costs of care per month of therapy were $2163 for risperidone and $2316 for olanzapine. Results from sensitivity analyses suggest that the probability of therapy discontinuation following weight gain >5 kg would have to be lower than 0.1 for the number of patients remaining on therapy at the end of 1 year to be the same for risperidone and olanzapine. CONCLUSIONS: Compared with risperidone, treatment with olanzapine may result in greater increases in body weight, higher rates of therapy discontinuation, and higher costs of medical-care services. 相似文献
105.
Carol J. Boyd PhD MSN FAAN Christian J. Teter PharmD Sean Esteban Mccabe PhD MSW 《The Journal of adolescent health》2004,34(6):531-534
During a school-based survey, middle and high school students (n = 1536) reported on their nonprescribed, lifetime use of asthma inhalers. Approximately 15% of 8th and 9th graders reported using nonprescribed asthma inhalers; the odds for this behavior were significantly higher for these students (2.25 and 2.30, respectively) and the nonprescribed use of asthma inhalers was significantly associated with higher rates of other drug use. 相似文献
106.
David Quintanar-Guerrero David Tamayo-Esquivel Adriana Ganem-Quintanar Eric Allémann Eric Doelker 《European journal of pharmaceutical sciences》2005,26(2):211-218
In this study, the emulsification-diffusion method traditionally used to prepare polymeric nanoparticles was adapted to obtain lipidic nanospheres (LN) using four model lipids. The method consists of dissolving the lipid in a partially water-miscible solvent (previously saturated with water) at room temperature or at controlled temperature depending on lipid solubility. This organic phase is emulsified in an aqueous solution of a stabilizing agent (saturated with solvent) by conventional stirring at the same temperature used to dissolve the lipid. This oil-in-water emulsion is then diluted with an excess of water at controlled temperature in order to provoke the diffusion from the internal phase into the external phase thereby causing lipid aggregation in the form of LN. This new approach for the preparation of LN has clear advantages over the existing methods, namely: (i) it is efficient and versatile; (ii) easy implementation and scaling up (with no need of high energy sources); (iii) high reproducibility and narrow size distribution; (iv) less physical stress (i.e., long exposure to high temperatures and to mechanical dispersion); (v) it is not necessary to dissolve the drug in the melted lipid. The selection of the water-miscible solvent and the stabilizers are critical parameters to obtain lipidic particles in the nanometric range. In general, solvents with high water miscibility and stabilizers able to form stable emulsions are preferred. The results demonstrated that it was possible to reduce the particle size by increasing the process temperature, the stirring rate, the amount of stabilizer, and by lowering the amount of lipid. Control of the preparative variables allowed to obtain LN with diameters under 100 nm. It was found that the influence of preparative parameters was associated with a mechanism based on a physicochemical instability. In this sense, it is suggested that the rapid solvent diffusion produces regions of local supersaturation near the interface, and LN are formed due to the ensuing interfacial phase transformations and lipid aggregation that occur in these interfacial domains. In terms of stability, only poly(vinyl alcohol) (PVAL) was able to preserve the physical stability of the dispersion for long periods after preparation. This effect was attributed to the ability of PVAL chains to form a strongly attached layer on the nanoparticle surface with an excellent repulsion effect. 相似文献
107.
108.
109.
In vitro development of engineered muscle using a scaffold based on the pressure‐activated microsyringe (PAM) technique 下载免费PDF全文
Daniele Cei Adriana Malena Carmelo de Maria Emanuele Loro Federica Sandri Giulia del Moro Sara Bettio Lodovica Vergani Giovanni Vozzi 《Journal of tissue engineering and regenerative medicine》2017,11(1):138-152
The development of new human skeletal muscle tissue is an alternative approach to the replacement of tissue after severe damage, for example in the case of traumatic injury, where surgical reconstruction is often needed following major loss of natural tissue. Treatment to date has involved the transfer of muscle tissue from other sites, resulting in a functional loss and volume deficiency of donor sites. Approaches that seek to eliminate these problems include the relatively new solution of skeletal muscle engineering. Here there are two main components to consider: (a) the cells with their regenerative potential; and (b) the polymeric structure onto which cells are seeded and where they must perform their activities. In this paper we describe well‐defined two‐ and three‐dimensional polymeric structures able to drive the myoblast process of adhesion, proliferation and differentiation. We examine a series of polymers and protein adhesions with which to functionalize the structures, and cell‐seeding methods, with a view to defining the optimal protocol for engineering skeletal muscle tissue. All polymer samples were tested for their mechanical and biological properties, to support the validity of our results in the real context of muscle tissue engineering. Copyright © 2014 John Wiley & Sons, Ltd. 相似文献